• Explore /
  • Poster
  • / Avelumab (MSB0010718C), an anti-PD-L1 antibody, as a third-line treatment in patients with advanced gastric or gastroesophageal junction cancer: A phase Ib JAVELIN Solid Tumor trial.

Avelumab (MSB0010718C), an anti-PD-L1 antibody, as a third-line treatment in patients with advanced gastric or gastroesophageal junction cancer: A phase Ib JAVELIN Solid Tumor trial.

Abstract Poster

Authors

null

Do-Youn Oh

Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea

Do-Youn Oh , Albert C. Lockhart , Deborah Jean Lee Wong , Matthew Hiram Taylor , Marcis Bajars , Anja von Heydebreck , Markus H. Moehler , Howard Safran

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach

Track

Cancers of the Esophagus and Stomach

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT01772004

Citation

J Clin Oncol 34, 2016 (suppl 4S; abstr TPS188)

DOI

10.1200/jco.2016.34.4_suppl.tps188

Abstract #

TPS188

Poster Bd #

O14

Abstract Disclosures

Similar Posters

First Author: Hyun Cheol Chung

First Author: Kohei Shitara

First Author: Timothy Jay Price

First Author: Thorsten Oliver Goetze